跳轉至內容
Merck
全部照片(1)

重要文件

SML1886

Sigma-Aldrich

VPC-13566

≥98% (HPLC)

同義詞:

2-(7-Methyl-1H-indol-3-yl)quinoline

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C18H14N2
CAS號碼:
分子量::
258.32
分類程式碼代碼:
51111800
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

CC1=CC=CC2=C1NC=C2C3=NC4=CC=CC=C4C=C3

InChI 密鑰

FPKBNOVQNMJTEJ-UHFFFAOYSA-N

生化/生理作用

VPC-13566 is Binding Function 3 (BF3)-specific inhibitor of the androgen receptor.
VPC-13566 is Binding Function 3 (BF3)-specific inhibitor of the androgen receptor. VPC-13566 potently inhibits AR transcriptional activity by displacement of the BAG1L peptide from the BF3 pocket. VPC-13566 inhibits the growth of various prostate cancer cell lines including an enzalutamide-resistant cell line and inhibits the growth of AR-dependent prostate cancer xenograft in mice.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Teresa Delgado-Goni et al.
Molecular cancer therapeutics, 15(12), 2987-2999 (2016-10-22)
Understanding the impact of BRAF signaling inhibition in human melanoma on key disease mechanisms is important for developing biomarkers of therapeutic response and combination strategies to improve long-term disease control. This work investigates the downstream metabolic consequences of BRAF inhibition
Eui Hyun Kim et al.
Journal of molecular endocrinology, 63(3), 175-185 (2019-08-14)
Oxidative stress (OS) is a major problem during in vitro culture of embryos. Numerous studies have shown that melatonin, which is known to have antioxidant properties, prevents the occurrence of OS in embryos. However, the molecular mechanisms by which melatonin
Nada Lallous et al.
Genome biology, 17, 10-10 (2016-01-28)
The androgen receptor (AR) is a pivotal drug target for the treatment of prostate cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR antagonists, such as hydroxyflutamide, bicalutamide, and enzalutamide, target the androgen binding site of the receptor

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務